Keywords

• N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine
• cas 162012-67-1
• carboxamide A 281

Quick Details

• ProName: N-(3-Chloro-4-fluorophenyl)-7-fluoro-6...
• CasNo: 162012-67-1
• Molecular Formula: C22H21Cl3N4O
• Appearance: powder
• Application: in research
• DeliveryTime: within 3-5 days after receiving the pa...
• PackAge: Aluminum foil bag/ as requirements
• Port: China main port
• ProductionCapacity: 800 Kilogram/Month
• Purity: 99.00%
• Storage: Store in a cool dry place and keep awa...
• Transportation: by air or by sea
• LimitNum: 10 Gram

Superiority

       Inner Mongolia Yong Ming Technology Co.,Ltd--- a worthy to be depended and trusted Pharmaceutical Intermediates company. We make sure the good quality product and reasonable price. We have the good after-sales service, to solve any kinds of problems, the goal is making every customer satisfy with our company and gain the best reputation.

There are variety of products for your choose. Please contact with us at any time.

Our promise:

1. Good quality product and reasonable price~ make customers happy and save customers’ money

2. Delivery product on time~ save customers’ time

3. Professional packing~let the customers receive it successfully

4. Many payment instruments~convenient to pay 

5. Service customers forever~ to establish long-term cooperation relationship

Welcome to your inquire and suggestions, everyone here do the best for you!

Details

• Product name: N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine

  Produc CAS:  162012-67-1

  Product application: the intermediates of afatinib,  pharmaceutical intermediates

  Delivery time: within 3 days after the payment

  Payment instrument: , bitcoin, moneygram

   

   

  4-(3-Chloro-4-fluorophenylamino)-7-fluoro-6-nitroquninazoline is an intermediate in the synthesis of Afatinib, an aminocrotonylamino-substituted quinazoline derivative used for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder.

  Afatinib, it is the second generation of highly efficient, double irreversible tyrosine kinase inhibitors.

   

   Erlotinib and gefitinib as tyrosine kinase inhibitors, inhibition of single EGFR, simultaneous inhibition of BIBW2992 two EGFR and HER-2 receptor. London Royal Gaye Hospital School of medicine in James Sr were studied in patients with various solid tumors, primary clinical study showed NSCLC patients with EGFR mutations can be obtained encouraging results, 20% of the patients with persistent PR (2 females and 1 males), including 2 cases of EGFR exon nineteenth the absence of this mutation was more common in women, non-smokers and patients with adenocarcinoma. BIBW2992 daily oral administration of 50mg is well tolerated. Phase II clinical studies of BIBW2992 show that, in patients with EGFR mutations, BIBW2992 still has potential for antitumor activity when it is resistant to the first generation of tyrosine kinase inhibitors (NSCLC). Because it is the only double inhibitory effect on EGFR and HER2 with non reversibility. In view of the excellent data from previous clinical studies, the drug was approved in February 15, 2008 through the US FDA rapid approval channel. An international multicenter phase III clinical trial will be conducted to investigate the use of BIBW2992 in NSCLC after the failure of previous epidermal growth factor receptor inhibitors, which will provide a possibility for NSCLC patients.

Welcome to your inquire, thanks in  advance.

More information: mona@nmg-ym.com

Skype: live:mona_3363